The use of radiosensitizing agents in the therapy of glioblastoma multiforme—a comprehensive review

• Published in: Strahlentherapie und Onkologie Vol. 198; no. 6; pp. 507 - 526
• Main Authors: Pepper, Niklas Benedikt, Stummer, Walter, Eich, Hans Theodor
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2022; Springer Nature B.V
• Subjects: Blood-brain barrier; Brain cancer; Medicine; Medicine & Public Health; Oncology; Radiation; Radiation therapy; Radiosensitizers; Radiotherapy; Review; Review Article; Radiosensitizer; Radiation therapy; Review; Glioblastoma
• ISSN: 0179-7158; 1439-099X; 1439-099X
• DOI: 10.1007/s00066-022-01942-1

Background Glioblastoma is the most common malignant brain tumor in human adults. Despite several improvements in resective as well as adjuvant therapy over the last decades, its overall prognosis remains poor. As a means of improving patient outcome, the possibility of enhancing radiation response by using radiosensitizing agents has been tested in an array of studies. Methods A comprehensive review of clinical trials involving radiation therapy in combination with radiosensitizing agents on patients diagnosed with glioblastoma was performed in the National Center for Biotechnology Information’s PubMed database. Results A total of 96 papers addressing this matter were published between 1976 and 2021, of which 63 matched the subject of this paper. All papers were reviewed, and their findings discussed in the context of their underlining mechanisms of radiosensitization. Conclusion In the history of glioblastoma treatment, several approaches of optimizing radiation-effectiveness using radiosensitizers have been made. Even though several different strategies and agents have been explored, clear evidence of improved patient outcome is still missing. Tissue-selectiveness and penetration of the blood–brain barrier seem to be major roadblocks; nevertheless, modern strategies try to circumvent these obstacles, using novel sensitizers based on preclinical data or alternative ways of delivery.